ES2791043T3 - Orientación de corroles para toxicidad tumoral e IRM - Google Patents

Orientación de corroles para toxicidad tumoral e IRM Download PDF

Info

Publication number
ES2791043T3
ES2791043T3 ES14794410T ES14794410T ES2791043T3 ES 2791043 T3 ES2791043 T3 ES 2791043T3 ES 14794410 T ES14794410 T ES 14794410T ES 14794410 T ES14794410 T ES 14794410T ES 2791043 T3 ES2791043 T3 ES 2791043T3
Authority
ES
Spain
Prior art keywords
tumor
nanoparticle
corrol
targeting
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14794410T
Other languages
English (en)
Spanish (es)
Inventor
Lali Medina-Kauwe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars-Sinai Medical Center
Original Assignee
Cedars-Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars-Sinai Medical Center filed Critical Cedars-Sinai Medical Center
Application granted granted Critical
Publication of ES2791043T3 publication Critical patent/ES2791043T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES14794410T 2013-05-08 2014-05-08 Orientación de corroles para toxicidad tumoral e IRM Active ES2791043T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361821106P 2013-05-08 2013-05-08
PCT/US2014/037234 WO2014182868A1 (en) 2013-05-08 2014-05-08 Targeting corroles for tumor toxicity and mri

Publications (1)

Publication Number Publication Date
ES2791043T3 true ES2791043T3 (es) 2020-10-30

Family

ID=51864925

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14794410T Active ES2791043T3 (es) 2013-05-08 2014-05-08 Orientación de corroles para toxicidad tumoral e IRM

Country Status (16)

Country Link
US (2) US9757386B2 (enExample)
EP (2) EP2993983B1 (enExample)
JP (1) JP6640715B2 (enExample)
KR (1) KR20160008523A (enExample)
CN (2) CN105307499B (enExample)
AU (2) AU2014262653B2 (enExample)
CA (1) CA2910030A1 (enExample)
DK (1) DK2993983T3 (enExample)
ES (1) ES2791043T3 (enExample)
IL (1) IL265935B (enExample)
MX (1) MX2015015434A (enExample)
PL (1) PL2993983T3 (enExample)
PT (1) PT2993983T (enExample)
RU (1) RU2674146C2 (enExample)
WO (1) WO2014182868A1 (enExample)
ZA (1) ZA201508092B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009441A2 (en) 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
JP6618360B2 (ja) 2012-08-03 2019-12-11 セダーズ−シナイ メディカル センター 薬物送達タンパク質の輸送向上変異体の単離
RU2674146C2 (ru) 2013-05-08 2018-12-07 Седарс-Синай Медикал Центр Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт
WO2015109264A1 (en) 2014-01-17 2015-07-23 Cedars-Sinai Medical Center Receptor targeting constructs and uses thereof
JP6728056B2 (ja) 2014-04-04 2020-07-22 シーダーズ—シナイ メディカル センター Ｈｅｒ３標的ナノ粒子によりトラスツズマブ耐性ｈｅｒ２＋乳癌を標的にすること
WO2019043711A1 (en) * 2017-08-31 2019-03-07 Technion Research & Development Foundation Limited COMPOSITIONS OF CORROLE

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA129822A (en) 1910-08-24 1910-12-13 The John Bertram And Sons Company, Limited Motor controlling apparatus
CA140995A (en) 1912-03-05 1912-06-11 Davydd C. Hughes Type plate mechanism
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
WO2002094318A1 (en) 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
DE60236870D1 (de) * 2001-07-02 2010-08-12 Technion Res & Dev Foundation Verfahren zur herstellung selektiv substituierter corrole und neue substituierte corrole
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2009009441A2 (en) 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2009027965A1 (en) 2007-08-28 2009-03-05 Technion Research And Development Foundation Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders
US20110098262A1 (en) * 2008-01-31 2011-04-28 Yondim Moussa B H Corroles for neuroprotection and neurorescue
WO2009151539A1 (en) 2008-05-24 2009-12-17 Sirnaomics, Inc. COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS
WO2010078517A2 (en) 2008-12-31 2010-07-08 Sirnaomics, Inc. Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
CN101704820A (zh) * 2009-09-24 2010-05-12 江苏大学 三(4-氯苯基)咔咯化合物及其合成方法
WO2011094335A2 (en) 2010-01-26 2011-08-04 Yale University Microrna signatures predicting responsiveness to anti-her2 therapy
MX2014001823A (es) * 2011-08-15 2014-08-21 Technion Res & Dev Foundation Combinaciones de corroles y estatinas.
JP6618360B2 (ja) 2012-08-03 2019-12-11 セダーズ−シナイ メディカル センター 薬物送達タンパク質の輸送向上変異体の単離
RU2674146C2 (ru) 2013-05-08 2018-12-07 Седарс-Синай Медикал Центр Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт
WO2015109264A1 (en) 2014-01-17 2015-07-23 Cedars-Sinai Medical Center Receptor targeting constructs and uses thereof
JP6728056B2 (ja) 2014-04-04 2020-07-22 シーダーズ—シナイ メディカル センター Ｈｅｒ３標的ナノ粒子によりトラスツズマブ耐性ｈｅｒ２＋乳癌を標的にすること
AU2017271662A1 (en) 2016-05-27 2018-12-06 Cedars-Sinai Medical Center Drug-delivery nanoparticles and treatments for drug-resistant cancer

Also Published As

Publication number Publication date
CA2910030A1 (en) 2014-11-13
AU2018250401B2 (en) 2020-06-11
CN105307499A (zh) 2016-02-03
CN105307499B (zh) 2018-04-27
HK1221870A1 (en) 2017-06-16
AU2018250401A1 (en) 2018-11-08
KR20160008523A (ko) 2016-01-22
RU2015152033A (ru) 2017-06-16
EP2993983A4 (en) 2017-01-11
PT2993983T (pt) 2020-05-22
EP2993983B1 (en) 2020-03-25
JP2016526021A (ja) 2016-09-01
RU2674146C2 (ru) 2018-12-07
US20170281802A1 (en) 2017-10-05
IL265935A (en) 2019-05-30
WO2014182868A1 (en) 2014-11-13
MX2015015434A (es) 2016-03-15
US20140335025A1 (en) 2014-11-13
US10709801B2 (en) 2020-07-14
CN108451930A (zh) 2018-08-28
EP3730155A1 (en) 2020-10-28
AU2014262653B2 (en) 2018-07-26
AU2014262653A1 (en) 2015-11-12
EP2993983A1 (en) 2016-03-16
PL2993983T3 (pl) 2020-09-07
DK2993983T3 (da) 2020-05-18
JP6640715B2 (ja) 2020-02-05
RU2015152033A3 (enExample) 2018-04-25
ZA201508092B (en) 2017-02-22
IL265935B (en) 2020-06-30
US9757386B2 (en) 2017-09-12

Similar Documents

Publication Publication Date Title
AU2018250401B2 (en) Targeting corroles for tumor toxicity and mri
Tan et al. Mitochondria-responsive drug release along with heat shock mediated by multifunctional glycolipid micelles for precise cancer chemo-phototherapy
Wang et al. Janus gold triangle-mesoporous silica nanoplatforms for hypoxia-activated radio-chemo-photothermal therapy of liver cancer
Zhang et al. Gold nanorods based platforms for light-mediated theranostics
Sun et al. VEGF-loaded graphene oxide as theranostics for multi-modality imaging-monitored targeting therapeutic angiogenesis of ischemic muscle
ES2227671T3 (es) Uso de una texafirina en la preparacion de un medicamento para usar con un agente quimioterapeutico en la quimiosensibilizacion del cancer.
Guven et al. Carbon nanotube capsules enhance the in vivo efficacy of cisplatin
Ren et al. Ultra-small Bi2S3 nanodot-doped reversible Fe (ii/iii)-based hollow mesoporous Prussian blue nanocubes for amplified tumor oxidative stress-augmented photo-/radiotherapy
Sawant et al. Cancer research and therapy: Where are we today
Liu et al. Near-infrared light-triggered nanobomb for in situ on-demand maximization of photothermal/photodynamic efficacy for cancer therapy
Wang et al. Self-assembly of photosensitive and radiotherapeutic peptide for combined photodynamic-radio cancer therapy with intracellular delivery of miRNA-139-5p
ES2627998T3 (es) Nanopartículas fluorescentes
Gao et al. Dual ligand-targeted Pluronic P123 polymeric micelles enhance the therapeutic effect of breast cancer with bone metastases
Kumar et al. Multifunctional liposomes to attain targeting, stimuli sensitive drug release and imaging cancer
US20230414759A1 (en) Novel cyclic peptides based on nanobiostructural control, peptidesomes with core/shell structure comprising same, and uses thereof
HK1221870B (en) Targeting corroles for tumor toxicity and mri
US20230060103A1 (en) Drug delivery systems and targeted release of pharmaceutical agents with focused ultrasound
HK1260403A1 (en) Targeting corroles for tumor toxicity and mri
WO2025246968A1 (en) Use of recombinant phage in cancer therapy
KR102851924B1 (ko) 바이오이미징용, 및 암의 진단 또는 치료용 복합체
KR20200135224A (ko) 마이셀 구조의 나노 전달체 및 이의 용도
Chakraborty et al. Emerging graphene-based nanomaterials for cancer nanotheranostics
Mahmudzade et al. Smart Nanotextiles for Controlled and Targeted Drug Release
WO2017144762A1 (es) Uso de un complejo gnp-llo91-99 para el tratamiento y la prevención del cáncer
박정하 Nucleus-targeted Gene and Anticancer Drug Delivery Using α-Synuclein-Gold Nanoparticle Conjugates